S2-E16 - Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment

S2-E16 — Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment

Mazen Noureddin joins the Surfers to discuss his work determining the cost-effectiveness of non-invasive NASH testing and treatment in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues.
()

Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment — Dr. Noureddin started the discussion by providing a history of cost-effectiveness research in NASH and NAFLD. At a population level, biopsy turns out never to be cost-effective while less expensive tests almost always are. As the group brainstormed implications and new questions, they touched on theories on how cost-effectiveness for F3 and F2 patients might differ, and even how chronic therapies and sequential use of specific medicines might reflect cost-effective issues. An enlightening way to think about testing and treatment today, and how these will evolve over time.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"